"instanceType","uuid:ID","versionIdentifier","rationale","id"
"StudyVersion","66b004f8-3c7d-4726-b14d-5b38da175451","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
